Last $4.25 USD
Change Today +0.07 / 1.67%
Volume 158.3K
ADMP On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

adamis pharmaceuticals corp (ADMP) Snapshot

Open
$4.18
Previous Close
$4.18
Day High
$4.37
Day Low
$4.01
52 Week High
12/5/13 - $11.90
52 Week Low
11/20/13 - $3.40
Market Cap
44.6M
Average Volume 10 Days
86.8K
EPS TTM
$-1.23
Shares Outstanding
10.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ADAMIS PHARMACEUTICALS CORP (ADMP)

Related News

No related news articles were found.

adamis pharmaceuticals corp (ADMP) Related Businessweek News

No Related Businessweek News Found

adamis pharmaceuticals corp (ADMP) Details

Adamis Pharmaceuticals Corporation, a biopharmaceutical company, is engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergies, oncology, and immunology. Its specialty pharmaceutical division has four products in its pipeline, including the Epinephrine Injection Pre-filled Syringe (PFS) for use in the emergency treatment of anaphylaxis; APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease (COPD); and APC-3000, a hydrofluoroalkane (HFA) inhaled nasal steroid product for the treatment of allergic rhinitis. The company’s biotechnology division focuses on the development of therapeutic vaccine product candidates and cancer drugs for patients with unmet medical needs in the global cancer markets. Its four products under development include TeloB-VAX, a novel cell-based therapeutic cancer vaccine for prostate cancer; and three drugs comprise APC-100, APC-200, and APC-300 for the treatment of prostate cancer. The company is headquartered in San Diego, California.

adamis pharmaceuticals corp (ADMP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $625.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $247.7K
Vice President of Operations
Total Annual Compensation: $225.0K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $287.7K
Compensation as of Fiscal Year 2014.

adamis pharmaceuticals corp (ADMP) Key Developments

Adamis Pharmaceuticals Corporation Auditor Raises 'Going Concern' Doubt

Adamis Pharmaceuticals Corporation filed its 10-K on Jun 23, 2014 for the period ending Mar 31, 2014. In this report its auditor, Mayer Hoffman McCann P.C., gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Adamis Pharmaceuticals Mulls Acquisitions

Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) which has filed a shelf registration in the amount of $50 million, is looking for acquisitions. Adamis Pharmaceuticals Corporation intends to use the net proceeds from the sale of the securities offered for general corporate purposes, which may include without limitation working capital, capital expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new companies, technologies or products, and the repayment, refinancing, redemption or repurchase of future indebtedness or capital stock.

Adamis Pharmaceuticals Corporation - Special Call

To provide a business update concerning the company's recent corporate developments

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADMP:US $4.25 USD +0.07

ADMP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Delcath Systems Inc $2.46 USD +0.03
View Industry Companies
 

Industry Analysis

ADMP

Industry Average

Valuation ADMP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADAMIS PHARMACEUTICALS CORP, please visit www.adamispharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.